en-us Mon, 15 Apr 2024 23:48:50 +0200 Mon, 15 Apr 2024 23:48:50 +0200 Mon, 15 Apr 2024 23:48:50 +0200 <![CDATA[Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S. ]]> here. With #FutureFresenius, Fresenius successfully set the course last year to become a leading therapy-focused company. In line with the strategy, Fresenius has simplified its structure, is sharpening its focus by concentrating on its operating companies Fresenius Kabi and Fresenius Helios and is continuously enhancing its performance.  About Tyenne®, a Tocilizumab Biosimilar Tyenne® (tocilizumab-aazg), a biosimilar to Actemra® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced analytical and manufacturing technologies for use in the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving the product. Tyenne® is contraindicated in patients with known hypersensitivity to tocilizumab products. For more information about Tyenne®, please see the full prescribing information for the U.S. here. Tyenne® demonstrates Fresenius Kabi’s commitment to providing access to affordable and cost-effective biosimilars to more patients living with autoimmune diseases around the world while enabling savings for health care systems. KabiCare, Fresenius Kabi’s comprehensive patient support program, will be available to patients and health care providers in the U.S. from launch.  About Fresenius Kabi  Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.  Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.  Following its strategy “Vision 2026”, which is a key part of the #FutureFresenius program of the Fresenius healthcare group, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders. *Tyenne® is a registered trademark of Fresenius Kabi Deutschland GmbH.  **Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.  ***Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries ****Stimufend® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries  ]]> Thu, 04 Apr 2024 20:30:13 +0200 <![CDATA[mAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment]]> Thu, 04 Apr 2024 20:00:00 +0200 <![CDATA[Fresenius Management Board buys own shares]]> Mon, 18 Mar 2024 17:00:00 +0100 <![CDATA[Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate]]> Fri, 08 Mar 2024 16:00:00 +0100 <![CDATA[Fresenius Supervisory Board extends contract of Chief Financial Officer Sara Hennicken ahead of time]]> Thu, 07 Mar 2024 17:00:00 +0100 <![CDATA[Fresenius Kabi’s biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and subcutaneous tocilizumab biosimilar approved by the FDA ]]> Wed, 28 Feb 2024 21:00:00 +0100 <![CDATA[Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP in the U.S.]]> Tue, 27 Feb 2024 14:14:54 +0100 <![CDATA[Fresenius appoints sustainability advisory board comprising internationally recognized ESG experts]]> Wed, 21 Feb 2024 14:00:00 +0100 <![CDATA[Fresenius closes 2023 with a strong fourth quarter and expects accelerated earnings growth in 2024 through increasing momentum from #FutureFresenius ]]> Tue, 20 Feb 2024 17:15:52 +0100 <![CDATA[Fresenius with top result in climate ranking, water ranking improved]]> Mon, 05 Feb 2024 19:00:00 +0100 <![CDATA[mAbxience announces CDMO agreement with Biosidus for the treatment of Fabry disease ]]> Wed, 31 Jan 2024 18:29:33 +0100 <![CDATA[Fresenius successfully completes divestment of fertility services group Eugin]]> Mon, 29 Jan 2024 22:00:00 +0100 <![CDATA[Fresenius Kabi launches generic drug for the treatment of serious fungal infections in the U.S.]]> Fri, 12 Jan 2024 17:28:39 +0100 <![CDATA[Fresenius signs Zero Health Gaps Pledge to promote equal opportunities in healthcare]]> Wed, 20 Dec 2023 15:00:00 +0100 <![CDATA[mAbxience announces licensing agreement with Intas for Etanercept biosimilar ]]> Fri, 15 Dec 2023 15:29:38 +0100 <![CDATA[ Fresenius Helios strengthens operational focus in digitalization]]> Thu, 14 Dec 2023 21:00:00 +0100 <![CDATA[Fresenius Kabi enters into multiyear supply and service agreement for its Ivenix Infusion System]]> Wed, 06 Dec 2023 00:07:54 +0100 <![CDATA[Fresenius makes use of the relief payments for increased energy costs provided for in the Hospital Financing Act ]]> Thu, 30 Nov 2023 16:15:36 +0100 <![CDATA[Fresenius successfully completes deconsolidation of Fresenius Medical Care ]]> Wed, 22 Nov 2023 04:12:49 +0100 <![CDATA[Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised]]>